BNCT is one of the cancer treatment methods that combine a neutron
irradiation device and a boron-containing drug, which has the
advantage to be able to treat once or in one day. It is a new concept of
cancer treatment method led by researchers in Japan, among other countries.
Kansai area was unique and suitable for BNCT research because
institutes in various fields such as medicine, pharmacy, and physics
were close to the Kyoto University Complex Atomic Energy Research
Institute, one of the world’s leading research center for BNCT clinical
studies. Since Stella Chemifa, our parent company that manufactures
boron 10, which is essential for BNCT, has been based in Osaka, it was
natural to meet BNCT and be involved in its development, and Stella Pharma was established.
Though many pieces of cancer research have conducted, there is no
single method that will cure cancer reliably. Currently, multidisciplinary
combination therapy with various modalities is commonly conducted.
Stella Pharma has been consistently involved in the practical
application of BNCT, a new type of radiotherapy, and played an
important role in this multidisciplinary cancer therapy since we started
business in Osaka in 2007. In May 2020, we launched the world’s
first boron-containing drug for BNCT. We believe that we took a new
application of BNCT, a new type of radiotherapy, and played an
step as a pharmaceutical company and the next stage of BNCT has begun at the same time.
To spread “a tool that will be a new light for people fighting cancer”
globally, we will continue to take on challenges. By stably providing
high quality drugs, we will strive for a reliable pharmaceutical company.
As a pioneer in the development of boron-containing drug for BNCT,
we also recognize that we have a social responsibility for future cancer therapy.
Listed on the Tokyo Stock Exchange Mothers leads us another growth
into a company that enables continuous business implementation.
Under a sound corporate management system, we will try our best to
gain the recognition and social credibility of BNCT and our company itself.